This is the authors' abstract. We don't add key points for this paper.
High grade astrocytic glioma (HGG) is a lethal solid malignancy with high recurrence rates and limited survival. While several cytotoxic agents have demonstrated efficacy against HGG, drug sensitivity testing platforms to aid in therapy selection are lacking. Patient-derived organoids (PDOs) have been shown to faithfully preserve the biological characteristics of several cancer types including HGG, and coupled with the experimental-analytical hybrid platform Quadratic Phenotypic Optimization Platform (QPOP) which evaluates therapeutic sensitivity at a patient-specific level, may aid as a tool for personalized medical decisions to improve treatment outcomes for HGG patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Toh et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: